Torrent Pharma recalls select batches of Semalix injection after Dr. Reddy's notice

Synopsis

Torrent Pharmaceuticals is voluntarily recalling select batches of its Semalix semaglutide injection pens. This action follows a product recall notification from its manufacturer, Dr. Reddy's Laboratories. Patient safety remains of paramount importance to the company during this process. There is no risk to patients currently using this specific treatment. All other Semaglutide products sold by Torrent remain unaffected.

Listen to this article in summarized format

Torrent Pharmaceuticals on Thursday said it is implementing a voluntary recall as a precautionary measure only for select batches of Semalix injection disposable pens used for treatment of diabetes.

"Patient safety is of paramount importance to us. There is no risk to patients already on this treatment because of this recall. Further, all other SKUs of Semaglutide being sold by Torrent including the oral formulation remain completely unaffected," according to a stock exchange filing by the company.

The recall is limited to select batches of Semalix Injection 2 mg and 4 mg manufactured by DRL. All other Semalix and Sembolic products, including tablets manufactured by Torrent, the 8 mg Semalix injection manufactured by MSN Laboratories, and the Sembolic reusable injection manufactured by Zydus Lifesciences, remain unaffected and continue to be available.

Earlier in the day, Dr Reddy's Laboratories said commercial supplies of its anti-diabetic drug semaglutide would be delayed for a certain period after certain batches failed quality specifications due to an issue with an ingredient.

In a regulatory filing, the company said there is no impact on patient safety and that it is investigating the root cause while taking corrective measures to ensure product quality.

"Certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (API) used in the product," the company said.